广誉远中药股份有限公司 2023 年半年度报告 公司代码：600771 公司简称：广誉远 广誉远中药股份有限公司 2023 年半年度报告 二〇二三年八月二十九日 1 / 172 广誉远中药股份有限公司 2023 年半年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实 性、准确性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 二、公司全体董事出席董事会会议。 三、本半年度报告未经审计。 四、公司负责人杨波、主管会计工作负责人王俊波及会计机构负责人（会计主管人员） 付守军声明：保证半年度报告中财务报告的真实、准确、完整。 五、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质 承诺，敬请投资者注意投资风险。 七、是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、是否存在违反规定决策程序对外提供担保的情况？ 否 九、是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整 性 否 十、重大风险 ...

证券代码：600771 证券简称：广誉远 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报 告中财务信息的真实、准确、完整。 (一)主要会计数据和财务指标 | --- | --- | --- | --- | |--------------------------------|---------------------|--------------------------|---------------------------------------------------| | 加权平均净资产收益率（%） | 0.57 \n本报告期末 | 增加 0.20 \n上年度末 | 个百分点 \n本报告期末比 上年度末增减 变动幅度 (%) | | 总资产 | 2,747,983,957.59 | 2,719,694,670.55 | 1.04 | | 归属于上市公司股东的所有者权益 | 1,711,496,344.27 | 1,701,705,891.16 | 0 ...

公司代码：600771 公司简称：广誉远 广誉远中药股份有限公司 2022 年年度报告 二○二三年四月二十二日 广誉远中药股份有限公司 2022 年年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、 准确性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 二、未出席董事情况 | --- | --- | --- | --- | |-------|--------|-----------------------------------------------------------------|-------| | | | 未出席董事职务 未出席董事姓名 未出席董事的原因说明 被委托人姓名 | | | 董事 | 刘兆维 | 工作原因 | 杨波 | | 董事 | 季占璐 | 工作原因 | 杨波 | 三、利安达会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报 告。 四、公司负责人杨波、主管会计工作负责人王俊波及会计机构负责人（会计主管人员） 付守军声明：保证年度报告中财务报告的真实、准确、完整。 五、董事会决议通过的本报告期利 ...

2022 年第三季度报告 单位：元 币种：人民币 1 / 12 证券代码：600771 证券简称：广誉远 广誉远中药股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | |------------------------------------------------|----------------|----------------------------------------|----------------|----------------------------- ...

广誉远中药股份有限公司 2022 年半年度报告 公司代码：600771 公司简称：广誉远 广誉远中药股份有限公司 2022 年半年度报告 二〇二二年八月二十四日 1 / 180 广誉远中药股份有限公司 2022 年半年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、 准确性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的 法律责任。 二、公司全体董事出席董事会会议。 三、本半年度报告未经审计。 四、公司负责人鞠振、主管会计工作负责人王俊波及会计机构负责人（会计主管人员） 付守军声明：保证半年度报告中财务报告的真实、准确、完整。 五、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承 诺，敬请投资者注意投资风险。 七、是否存在被控股股东及其关联方非经营性占用资金情况 否 八、是否存在违反规定决策程序对外提供担保的情况？ 否 九、是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、重大风险提示 ...

公司代码：600771 公司简称：广誉远 广誉远中药股份有限公司 2021 年年度报告 二○二二年四月三十日 广誉远中药股份有限公司 2021 年年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、 准确性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的 法律责任。 二、公司全体董事出席董事会会议。 三、利安达会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报 告。 四、公司负责人鞠振、主管会计工作负责人王俊波及会计机构负责人（会计主管人员） 付守军声明：保证年度报告中财务报告的真实、准确、完整。 五、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 经利安达会计师事务所（特殊普通合伙）审计确认，公司2021年度实现归属于母公 司所有者的净利润-31,624.44万元，年末累计未分配利润（母公司）为-59,389.95万元。 由于累计未分配利润为负，不具备分配条件，因此本年度不进行利润分配，也不进行资 本公积金转增股本。 六、前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资 ...

广誉远中药股份有限公司 2022 年第一季度报告 单位：元 币种：人民币 证券代码：600771 证券简称：广誉远 广誉远中药股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报 表信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 （一）主要会计数据和财务指标 | --- | --- | --- | --- | |----------------------------------------------|------------------|--------------------------------|------------------------------------------| | 项目 | 本 ...

广誉远中药股份有限公司 2021 年第三季度报告 单位：元 币种：人民币 证券代码：600771 证券简称：广誉远 广誉远中药股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中 财务报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一）主要会计数据和财务指标 | --- | --- | --- | --- | --- | |-----------------------------------------------|----------------|----------------------------------------|-----------------|-------------------- ...

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 432,558,335.54, a decrease of 13.22% compared to the same period last year[24]. - The net profit attributable to shareholders of the listed company was CNY 43,440,688.96, down 210.69% year-on-year[24]. - The net profit after deducting non-recurring gains and losses was CNY 26,927,054.37, a decline of 340.88% compared to the previous year[24]. - The total assets at the end of the reporting period were CNY 3,797,965,909.49, a decrease of 9.07% from the end of the previous year[24]. - The net assets attributable to shareholders of the listed company were CNY 2,412,130,935.42, down 1.99% from the end of the previous year[24]. - Basic earnings per share for the first half of 2021 were CNY -0.10, a decrease of 211.11% year-on-year[25]. - The diluted earnings per share were also CNY -0.10, reflecting the same percentage decrease[25]. - The weighted average return on net assets was -2.01%, a decrease of 3.84 percentage points compared to the previous year[25]. - The comprehensive gross margin decreased by 8.38 percentage points year-on-year, influenced by changes in the sales proportion of different gross margin products, rising raw material prices, and increased sales support for key commercial clients[29]. - The basic (diluted) earnings per share decreased by 211.11% year-on-year, mainly due to the decline in net profit during the reporting period[29]. Cash Flow and Assets - The net cash flow from operating activities was CNY -126,559,912.53, with no applicable comparison[24]. - The net cash flow from operating activities increased by 155.10 million yuan compared to the same period last year, primarily due to a 226.87 million yuan increase in cash received from sales of goods, representing a growth of 66.37%[29]. - The company reported a total asset of 3.453 billion yuan and a net asset attributable to shareholders of 2.364 billion yuan as of June 30, 2021[73]. - Cash and cash equivalents decreased by 55.50% to CNY 175,191,825.98, primarily due to the redemption of bank acceptance bills[112]. - Accounts receivable decreased by 8.94% to CNY 1,420,231,515.01, maintaining a stable proportion of total assets at 41.13%[112]. - Inventory decreased by 7.29% to CNY 336,239,051.09, representing 9.74% of total assets[112]. Market and Industry Trends - The pharmaceutical manufacturing industry in China achieved an operating income of CNY 1,404.69 billion, representing a year-on-year growth of 28.0%[51]. - The total profit for the pharmaceutical manufacturing sector reached CNY 300.04 billion, with a remarkable year-on-year increase of 88.88%[51]. - The Chinese pharmaceutical manufacturing industry's industrial added value grew by 29.6% year-on-year, outperforming the overall industrial growth rate by 13.7 percentage points[51]. - The market for traditional Chinese medicine manufacturing is projected to reach CNY 75.3 billion in 2021, showing an upward trend[54]. Product and R&D Development - The company has 104 drug registration certificates, 1 health food license, and 1 liquor license, with 36 drugs listed in the National Essential Medicines List (2018 edition)[37]. - The company’s core products, including Gui Ling Ji and Ding Kun Dan, have been recognized as national intangible cultural heritage, highlighting the company's historical significance and brand image[37]. - The company is engaged in the production and sales of traditional Chinese medicine, with its core business divided into traditional Chinese medicine, premium Chinese medicine, and health wine[37]. - The company has increased its R&D investment in the "Zhiliao Youfang APP" project by CNY 2,591,000, reflecting a significant increase of 959.00%[112]. - The company has 26 ongoing research projects and has published over 200 related papers, including 13 in SCI journals[64]. - The company owns 20 patents, with 2 new patents successfully applied for during the reporting period[66]. Sales and Marketing Strategies - The company has strengthened its marketing strategies, including increasing sales support for key commercial clients and enhancing consumer education activities[72]. - The company is actively expanding its sales channels through various models, including cooperative distribution and agency sales[49]. - E-commerce sales during the 618 mid-year promotion increased by 129% compared to the same period in 2020, with overall sales up by 46% in the reporting period[81]. - The company added 31 new terminal stores and 14 new agents, bringing the total number of terminal stores to nearly 300 by June 30, 2021[82]. - The OTC division optimized terminal sales strategies, achieving a 50% year-on-year increase in traditional Chinese medicine receivables and improved inventory management[80]. Environmental and Compliance Measures - The company has established a wastewater treatment facility with a processing capacity of 15m³/h, ensuring that all pollutants are discharged within the standards[150]. - The company has implemented a third-party environmental monitoring program to ensure compliance with discharge standards[151]. - The company has established an emergency response plan for environmental incidents, which has been filed with the local environmental bureau[154]. - The company's pollution control facilities are reported to be in good operating condition, with all pollutants meeting discharge standards[158]. Governance and Management Changes - The company held its first extraordinary shareholders' meeting on January 21, 2021, where two proposals were approved, including changes to the company's registered address and amendments to certain articles of association[139]. - The 2020 annual shareholders' meeting was held on May 28, 2021, approving seven proposals, including the 2020 annual work report and financial budget for 2021[140]. - There were changes in senior management, with Yang Hongfei resigning as director and executive vice president, and Zheng Yanli resigning as director and vice president due to work changes[143]. - The company has committed to maintaining independence from its controlling shareholder in terms of assets, personnel, and operations[165]. Risks and Challenges - The company faces risks from intensified industry policies and market competition, which may lead to significant changes in operational models and competitive landscapes due to ongoing healthcare reforms and regulatory measures[126]. - The company is actively managing accounts receivable risks, which are high due to long payment cycles in the medical industry, and is implementing stricter collection policies to improve cash flow[127]. - The company is addressing raw material supply and price volatility risks by enhancing inventory management and establishing strategic partnerships with suppliers to ensure stable pricing and quality[131]. - The company emphasizes quality control in its production processes to mitigate quality safety risks, adhering to national regulations and enhancing training for staff to prevent quality incidents[136].